BioLife Solutions (NASDAQ:BLFS) Upgraded at StockNews.com

StockNews.com upgraded shares of BioLife Solutions (NASDAQ:BLFSGet Rating) to a sell rating in a research note published on Monday.

Other equities research analysts also recently issued reports about the company. Cowen lowered their target price on BioLife Solutions to $29.00 in a report on Monday, August 15th. Stephens lowered their target price on BioLife Solutions to $31.00 in a report on Wednesday, November 16th.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $21.55 on Monday. The stock’s 50 day moving average is $21.94 and its 200 day moving average is $19.27. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.68 and a quick ratio of 2.76. The firm has a market cap of $921.69 million, a P/E ratio of -8.69 and a beta of 1.78. BioLife Solutions has a one year low of $10.40 and a one year high of $45.40.

Insiders Place Their Bets

In other news, COO Greef Roderick De sold 1,233 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $21.95, for a total transaction of $27,064.35. Following the completion of the sale, the chief operating officer now owns 125,271 shares in the company, valued at $2,749,698.45. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, COO Greef Roderick De sold 1,233 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $21.95, for a total transaction of $27,064.35. Following the completion of the sale, the chief operating officer now owns 125,271 shares in the company, valued at $2,749,698.45. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Amy Duross sold 2,600 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $24.35, for a total value of $63,310.00. Following the sale, the director now owns 18,157 shares of the company’s stock, valued at approximately $442,122.95. The disclosure for this sale can be found here. Over the last three months, insiders sold 53,982 shares of company stock worth $1,236,593. 3.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its position in shares of BioLife Solutions by 802.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,218 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 1,083 shares during the last quarter. Wipfli Financial Advisors LLC purchased a new position in shares of BioLife Solutions during the third quarter valued at approximately $29,000. Nisa Investment Advisors LLC boosted its position in shares of BioLife Solutions by 439.3% during the third quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 1,230 shares during the last quarter. KBC Group NV purchased a new position in shares of BioLife Solutions during the second quarter valued at approximately $36,000. Finally, Point72 Hong Kong Ltd purchased a new position in shares of BioLife Solutions during the first quarter valued at approximately $36,000. Institutional investors own 86.69% of the company’s stock.

About BioLife Solutions

(Get Rating)

BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

Recommended Stories

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.